Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Download bibliography of all 5,209 studies, highest score first: BibTeX (.bib) · RIS (.ris)
Highest usefulness score first. Studies without a score come last.
-
More years of education have been found to be associated with a lower rate of Alzheimer disease (AD) in individuals without intellectual disability.
Why it matters
In 35 adults with Down syndrome, a higher level of cognitive functioning predicted less decline after the effect of age was removed, while educational level, years in an institution and employment were not directly associated with decline. This is an observational study and does not test a treatment, cure or prevention for Alzheimer's disease.
-
Twenty-seven patients with Alzheimer-type dementia (ATD) were treated with bright light therapy in the morning for four consecutive weeks.
Why it matters
This study treated 27 people with Alzheimer-type dementia with bright light therapy for four weeks and found it improved circadian rhythm disturbances and MMSE scores, especially in early stages, though it caused no remarkable effects on dementia severity. It is a small study of a non-drug therapy, not a cure or prevention.
-
In Alzheimer disease brains, the amyloid plaques are closely associated with a locally induced, nonimmune-mediated, chronic inflammatory response without any apparent influx of leukocytes from the blood.
Why it matters
This review argues that inflammation around amyloid plaques is an early event in Alzheimer disease and that anti-inflammatory drugs might prevent or slow the disease based on epidemiologic studies. It presents no new trial results, so whether anti-inflammatory treatment actually helps patients remains unproven.
-
The emergence of drugs that may slow progression of Alzheimer disease, if administered early during its course, has necessitated early diagnosis of the disease itself.
Why it matters
This review describes positron emission tomography findings of metabolic deficits in the temporal and parietal lobes in Alzheimer disease and in nondemented people at risk, including those with Down syndrome. It discusses early diagnosis and notes the findings need confirmation in larger prospective studies, and does not present a treatment or cure.
-
Senile plaques and neurofibrillary tangles are the markers of Alzheimer's disease.
Why it matters
This prospective clinicopathological study describes senile plaques and neurofibrillary tangles as markers of Alzheimer's disease that are also found in some intellectually normal older people, referred to as physiological aging. It describes the progression of lesions rather than reporting a treatment, cure or prevention.
-
Two suggested clinical trial designs for assessing progression of Alzheimer disease are the randomized withdrawal design and the randomized start design.
Why it matters
This is a position paper discussing trial designs for measuring whether a drug slows Alzheimer's disease progression, not a study of any treatment. It notes that the randomized start design has potential but that design, ethical, and statistical issues remain unsolved before it can be used.
-
Magnetic resonance imaging is potentially a valuable tool in the diagnosis of Alzheimer disease in adults with Down syndrome, particularly in individuals for whom standard intellectual assessments are not possible.
Why it matters
This single case study of one elderly man with Down syndrome and Alzheimer's disease found that MRI changes in temporal and hippocampal regions correlated with his clinical deterioration and with neuropathological findings of Alzheimer's disease. The authors conclude MRI is potentially a valuable diagnostic tool for Alzheimer's disease in adults with Down syndrome, particularly when standard intellectual assessments are not possible.
-
35/100
Alzheimer disease is a common condition that severely affects both persons with the illness and their families.
Why it matters
This paper discusses whether a large trial of antioxidant nutrients for preventing Alzheimer's disease would be worthwhile, based on laboratory and observational findings. It reports no trial results and provides no evidence that antioxidants prevent the disease.
-
Evolutionary aspects of menopause are considered from several perspectives.
Why it matters
This paper discusses evolutionary aspects of ovarian oocyte decline and raises the idea of hormonal intervention strategies, based partly on mouse studies. It proposes hypotheses only and reports no proven treatment, cure or prevention for Alzheimer's disease.
-
Postmortem morphometric analyses of Bielschowsky stained sections from brains of 70 mentally retarded people without Down syndrome, age 65 and over when they died, indicated Alzheimer-type neuropathology in 22 cases (31%) and a majority with at least presence of some Alzheimer-type lesions.
Why it matters
This postmortem study found Alzheimer-type neuropathology in 31% of mentally retarded people without Down syndrome aged 65 and over, and identified possible clinical indicators of Alzheimer's disease in otherwise healthy individuals. It describes prevalence and symptoms but does not test any treatment or prevention.
-
APOE and PICALM are prominent risk genes for late-onset Alzheimer’s disease (AD).
Why it matters
The protective PICALM rs3851179 A allele was associated with lower Alzheimer's disease risk only among APOE ε4 carriers, and plasma SNAP25 was identified as a protein associated with both APOE ε4 and PICALM rs3851179. No CSF protein survived multiple-testing correction.
-
Enhanced connectivity between attention networks may be a characteristic of CR benefits in individuals with mild Alzheimer disease.
Why it matters
In this pilot resting-state fMRI study, cognitive rehabilitation in people with mild Alzheimer's disease was followed by increased connectivity between the dorsal and ventral attention networks, and greater autonomy in daily activities was associated with stronger connectivity between these networks. The authors conclude that enhanced connectivity between attention networks may be a characteristic of cognitive rehabilitation benefits, but this is a pilot study and does not show a cure or prevention.
-
Are amyloid-targeting monoclonal antibodies safe and effective for mild cognitive impairment (MCI) or Alzheimer disease?
Why it matters
This review of randomized controlled trials of monoclonal antibodies for patients with dementia or mild cognitive impairment found no clinically meaningful improvements in cognitive scores. It directly addresses whether amyloid-targeting monoclonal antibodies are safe and effective for these patients.
-
Agreement between Syngo.via and MIMneuro varied by region.
Why it matters
Two commercial amyloid PET analysis platforms showed overall agreement, but regional results varied and differences were greatest in the intermediate-amyloid group. Because these differences may affect treatment eligibility in borderline cases, Z-scores from different platforms should not be used interchangeably without cross-validation.
-
Eight proteins were differently expressed in carriers with larger WMH volumes (Figure 1).
Why it matters
In carriers of autosomal dominant Alzheimer's disease, higher CSF levels of matrix metalloproteinase-12 were found in those with severe cerebral microhemorrhages, suggesting MMP12 may be a marker for microhemorrhage risk. This is a biomarker association study and does not test a treatment or cure.
-
Keeping current with the burden and risk factors of Alzheimer disease and other dementias (ADOD) from global to national levels is critical for healthcare planning, prevention strategies, and the allocation of resources.
Why it matters
This descriptive analysis of global burden of disease data from 1990 to 2021 found escalating age-standardized Alzheimer's disease and other dementias rates with notable geographical disparities and an association with metabolic risk factors. The authors call for geographically targeted public health strategies aligned with predominant risk factors, but no treatment, cure, or prevention was tested.
-
The results showed that the best validation scores were achieved by the CNN-LSTM model after integrating clinical attributes, with an accuracy of 92.47%.
Why it matters
A deep learning model using fMRI data and clinical attributes predicted progression from mild cognitive impairment to Alzheimer's disease with 92.47% accuracy. This is a prediction tool, not a treatment, cure or prevention for Alzheimer's disease.
-
CSF pTau181/Ab42 ratio is a diagnostic marker for Alzheimer disease correlated well with PET scan compared to various standalone cognitive screening assessment.
Why it matters
This study found that the CSF pTau181/Ab42 ratio correlated well with PET scan findings and had a sensitivity of 76.2% and specificity of 84.2% for identifying Alzheimer's disease. It is about diagnosis, not treatment, and does not demonstrate any cure or prevention.
-
Most Alzheimer disease (AD) susceptibility genes have poorly understood roles in the central nervous system (CNS).
Why it matters
Using fruit flies, this study characterized 100 conserved candidate Alzheimer's disease risk genes and identified 50 with requirements for nervous system structure or function, plus 28 that modify amyloid-beta or tau neurotoxicity. This is a cross-species genetic screen that may inform understanding of risk pathways, but it does not test a treatment or cure.
-
This study aimed to investigate the bidirectional causal relationship between celiac disease (CD) and the risk of Alzheimer disease (AD) or frontotemporal dementia (FTD) using Mendelian randomization (MR), in order to clarify prior inconsistent findings.
Why it matters
This Mendelian randomization study found no evidence of a causal effect between celiac disease and either Alzheimer disease or frontotemporal dementia in either direction. The authors conclude the association is likely noncausal, and no treatment, cure, or prevention is reported.
-
The accuracy of α-synuclein-SAA for DLB was 87% (95% confidence interval [CI]: 77% to 98%) in CSF, 85% (95% CI: 75% to 98%) in skin, 58% (95% CI: 47% to 69%) in olfactory mucosa, and 59% (95% CI: 51% to 66%) in urine.
Why it matters
The α-synuclein seed amplification assay showed high accuracy in cerebrospinal fluid and skin for diagnosing dementia with Lewy bodies. This is a diagnostic tool and does not treat, cure, or prevent Alzheimer's disease.
-
Neuroinflammation, mediated by activated microglia and astrocytes, exacerbates Aβ and tau pathology, contributing to synaptic loss and neuronal death.
Why it matters
This review states that monoclonal antibodies can reduce amyloid burden and slow cognitive decline, with donanemab and lecanemab showing benefit in early disease, while aducanumab was discontinued in 2024. It notes that adverse events such as amyloid-related imaging abnormalities remain a significant concern, especially in APOE-4 carriers.
-
LCN2 is not only a potential biomarker for the early diagnosis of AD but may also play a significant role in the neurodegenerative processes associated with the disease.
Why it matters
This study found that cerebrospinal fluid LCN2 levels were significantly higher in Alzheimer's disease patients than in those with mild cognitive impairment or no cognitive impairment, and were associated with cognitive decline, Aβ deposition, and reduced cortical thickness but not tau phosphorylation. It does not test a treatment or cure, but it suggests LCN2 may be a potential diagnostic and progression biomarker.
-
It was found that the top cited 100 articles came from 51 journals and 31 countries.
Why it matters
This bibliometric analysis of the top 100 cited articles describes trends in artificial intelligence for Alzheimer's diagnosis and prediction. It maps the literature and does not test any treatment, cure or prevention.
-
The development of more effective disease-modifying treatments for Alzheimer's disease (AD) is compromised by the lack of streamlined measures to detect and monitor the full spectrum of neurodegeneration, including white matter pathology, which begins early.
Why it matters
In a rat model of Alzheimer's-type brain changes, a blood-based test using serum extracellular vesicles detected some markers of Alzheimer's and oxidative stress seen in brain tissue. This is early animal research, and the authors suggest such a liquid biopsy approach could potentially help detect and monitor some aspects of this type of neurodegeneration, but it has not been tested in people.
From across this topic
10 of the 5,172 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Atrial fibrillation in stroke-free patients is associated with memory impairment and hippocampal atrophy
- Remote and unsupervised digital memory assessments can reliably detect cognitive impairment in Alzheimer's disease
- Alpha-lipoic acid as a new treatment option for Alzheimer [corrected] type dementia
- Research progress in predicting the conversion from mild cognitive impairment to Alzheimer’s disease via multimodal MRI and artificial intelligence
- Omega-3 fatty acids and dementia
- The social construction of Aduhelm in the context of pharmaceutical ambiguity: exploring narratives from informal caregivers, medical professionals, and redditors on r/Alzheimers
- Donanemab in Early Alzheimer's Disease
- Serum magnesium is associated with the risk of dementia
- Assessment of the genetic variance of late-onset Alzheimer's disease
- MicroRNA expression in extracellular vesicles as a novel blood-based biomarker for Alzheimer's disease